Abbvie-Header Abbvie-Header

X

Find Novel Immunology Drugs in Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Flavonol glycoside analouges

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: ActoPharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 26, 2021

            Details:

            The biopharmaceutical formulation consisting of two flavanol glycoside analogues is designed to simultaneously reduce viral load, decrease platelet aggregation and modulate the cytokine ratios in order to effectively suppress cytokine storm.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ibudilast,Interferon-beta

            Therapeutic Area: Immunology Product Name: MN-166

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 29, 2020

            Details:

            The allowed claims cover a method of alleviating the negative effects of progressive multiple sclerosis, treating progressive multiple sclerosis, or slowing the progression of progressive multiple sclerosis by administering MN-166 and interferon-beta in separate dosage forms.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TRK-001

            Therapeutic Area: Immunology Product Name: TRK-001

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 19, 2020

            Details:

            TRK-001 is an autologous regulatory T-cell therapy that utilizes a patient’s own cells that are expanded ex vivo and infused back into the patient after a solid organ transplant.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Epinephrine

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 10, 2020

            Details:

            The preclinical results described in the publications were used to support the advancement of BRYN-NDS1C into the human clinical trial program currently underway.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ADP101

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Gurnet Point Capital

            Deal Size: $60.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing February 20, 2020

            Details:

            Proceeds to support clinical advancement of ADP101, a broad-spectrum oral biopharmaceutical candidate targeting food allergy.